Lectroject's Medical Report

Lectroject Particle Transport Unit, as a Carrier of Specific Anti-Virals.

The Lectroject iontophoretic drug delivery device was perfected in 2001 at which time it went to trial. An appeal was published in the news media for volunteers suffering from Herpes, CMV, Coxsackie and HIV. The response was disappointing, with only two HIV/AIDS patients willing to participate.

Herpes sufferers were numerous, but out of fear of some stigma associated with STD’s 90% would not allow their names to be used in any way, not even to colleagues of ours. 300 volunteers took part in this double blind trial.

Volunteers were all between the ages of 25 and 45 years with exception of one person aged 61 years and two teenagers. Male and female were equal in numbers. 90% were either unmarried or divorced. All volunteers were in the upper income bracket.

Group Trial Results:

Subjects undergoing treatment were tested by Independent Laboratories before and after undergoing treatment. In each case, ten treatments at 48 hour intervals were given.

Mode of Action

The electronic module creates an ionic stream through the patient. The Lectroject System emits a particle which follows the ionic stream to the + electrode. A small quantity of Acyclovir is placed under the applicator pads. The particle tacks through the Acyclovir, collects an atom of the medication and deposits in the affected cell where it interferes with the viral DNA and so prevents replication, the virus becomes dormant and is eventually eliminated from the body in a normal way. (By catabolism)

Action of Medication in Herpes

i.e. Anabolism and catabolism is known as metabolism. Once the DNA of the virus is interfered with, it cannot affect other cells (the virus is quarantined), and as the old cell is replaced by a new, unaffected cell, the viral particle is removed from the body.